Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three ...

More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again ...

Despite being thrown off its rhythm twice already, Johnson & Johnson is making another go of its “Texas two-step” strategy to ...

Telix Pharmaceuticals tallied its third acquisition of the year with a deal worth up to $250 million for Florida-based RLS ...

For trade group the Pharmaceutical Research and Manufacturers of America (PhRMA), the fight against pricing provisions in the ...

Swiss anti-aging biotech Rejuveron is seeking its rejuvenation as it morphs into Centenara Labs. | Swiss anti-aging biotech ...

Unlock the potential of patient support data with effective information governance. Manage risks, ensure compliance, and ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...